Sinopsis
Podcast by Cytokine Signalling Forum
Episodios
-
Discussing Rheumatology: Safety of filgotinib, and tofacitinib in pJIA
23/12/2021 Duración: 08minProf Iain McInnes reviews two papers this month, and discusses exposure-adjusted incidence rates of TEAEs and AESIs with filgotinib, as well as the efficacy and safety of tofacitinib in pJIA. Keep up to date with the latest in arthritis and cytokine signalling with Prof Iain McInnes. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.
-
Author Interview: Professor Kevin Winthrop (December 2021)
23/12/2021 Duración: 22minProfessor Kevin Winthrop, Professor of Medicine at Oregon Health & Science University. Join Professor Peter Nash as he interviews authors of recent notable papers in rheumatology. In this edition, Professor Kevin Withrop discusses his paper on the safety of filgotinib in patients with RA.
-
Author Interview: Professor Kevin Winthrop (November 2021)
22/12/2021 Duración: 20minProfessor Kevin Winthrop, Professor of Medicine at Oregon Health & Science University. Join Professor Peter Nash as he interviews authors of recent notable papers in rheumatology. In this edition, Professor Kevin Withrop discusses his paper on the incidence and risk of herpes zoster in patients with RA receiving upadacitinib.
-
Insights at ACR 2021: Basic Science / Beyond RA
14/12/2021 Duración: 40minGain insight into the latest research presented at ACR 2021. Experts review their congress posters and presentations on cytokine signalling and JAK inhibitors.
-
Insights at ACR 2021: PROs and JAK Treatment
13/12/2021 Duración: 48minGain insight into the latest research presented at ACR 2021. Experts review their congress posters and presentations on cytokine signalling and JAK inhibitors.
-
Insights at ACR 2021: Clinical Outcomes in RA
12/12/2021 Duración: 47minGain insight into the latest research presented at ACR 2021. Experts review their congress posters and presentations on cytokine signalling and JAK inhibitors.
-
Insights at ACR 2021: JAKs in Spondyloarthritis
11/12/2021 Duración: 30minGain insight into the latest research presented at ACR 2021. Experts review their congress posters and presentations on cytokine signalling and JAK inhibitors.
-
Insights at ACR 2021: COVID-19 Vaccination and Rituximab
10/12/2021 Duración: 31minGain insight into the latest research presented at ACR 2021. Experts review their congress posters and presentations on cytokine signalling and JAK inhibitors.
-
Insights at ACR 2021: Impact of COVID-19 on Practice
09/12/2021 Duración: 39minGain insight into the latest research presented at ACR 2021. Experts review their congress posters and presentations on cytokine signalling and JAK inhibitors.
-
Insights at ACR 2021: COVID Vaccinations
07/12/2021 Duración: 40minGain insight into the latest research presented at ACR 2021. Experts review their congress posters and presentations on cytokine signalling and JAK inhibitors.
-
Author Interview: Professor Atul Deodhar
06/12/2021 Duración: 24minProfessor Atul Deodhar, professor of medicine at Oregon Health & Science University. Join Professor Peter Nash as he interviews authors of recent notable papers in rheumatology. In this edition, Professor Atul Deodhar discusses his review on JAK-STAT signalling in spondyloarthritis and what that means for the use of JAK inhibitors for SpA treatment.
-
Discussing Rheumatology: Risk of HZ with UPA, and JAKs in SpA
06/12/2021 Duración: 08minProf Iain McInnes reviews two papers this month, and discusses the increased risk of HZ infection with upadacitinib, as well as the role of the JAK-STAT pathway in SpA pathenogenesis. Keep-up to date with the latest in arthritis and cytokine signalling with Prof Iain McInnes. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.
-
Author Interview: Professor Roy Fleischmann
18/11/2021 Duración: 28minProfessor Roy Fleishmann, clinical professor of medicine at the University of Texas Southwestern Medical Center. Join Professor Peter Nash as he interviews authors of recent notable papers in rheumatology. In this edition, Professor Roy Fleishmann discusses the effect of baricitinib on inhibiting radiographic progression of structural joint damage over 5 years in patients with active RA.
-
ACR 2021: Day 4 Highlights
09/11/2021 Duración: 26minGrace Wright presents the Day 4 highlights of the key abstracts and posters presented at ACR 2021.
-
ACR 2021: Day 3 Highlights
08/11/2021 Duración: 21minProfessor Leonard Calabrese presents the Day 3 highlights of the key abstracts and posters presented at ACR 2021.
-
ACR 2021: Day 2 Highlights
07/11/2021 Duración: 23minGrace Wright presents the Day 2 highlights of the key abstracts and posters presented at ACR 2021.
-
Discussing Rheumatology: Herpes Zoster and HBV
04/11/2021 Duración: 07minProf Iain McInnes discusses the risk of herpes zoster in RA patients taking biologics and DMARDS. He also discusses reactivation of hepatitis B in patients with RA taking tofacitinib. Keep-up to date with the latest in arthritis and cytokine signalling with Prof Iain McInnes. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.
-
ACR 2021: Day 1 Highlights
04/11/2021 Duración: 10minProf Calabrese presents the Day 1 highlights of the key abstracts and posters presented at ACR 2021.
-
ACR 2021 Preview Podcast
04/11/2021 Duración: 13minA preview of the latest research at ACR 2021. Prof Ritchlin highlights important abstracts in cytokine signalling at the upcoming ACR Convergence.
-
Rheumatology Author Professor Paul Bird: Tofacitinib Effectiveness
14/10/2021 Duración: 19minPaul Bird, Conjoint Professor at the University of South Wales. Join Professor Peter Nash as he interviews authors of recent notable papers in rheumatology. In this edition, Dr Paul Bird assess the real‑world evaluation of effectiveness, persistence, and usage patterns of monotherapy and combination therapy tofacitinib in treatment of rheumatoid arthritis in Australia.